

CURRICULUM VITAE

ALI AYOUB BAZZI, M.D.

PERSONAL INFORMATION

PLACE OF BIRTH: Caracas, Venezuela

LANGUAGES SPOKEN: English, Spanish, Arabic

OFFICE ADDRESS:

Primary
21097 NE 27th Court, Suite 100
Aventura, Fl. 33180
305-792-0012

Secondary
601 N. Flamingo Road, Suite 407
Pembroke Pines, Fl. 33028
954-524-0860

EDUCATIONAL BACKGROUND

FELLOWSHIP July 1989- June 1991	MOUNT SINAI MEDICAL CENTER FELLOWSHIP IN CARDIOLOGY 4300 Alton Road Miami, Beach, Fl. 33140
RESIDENCY July 1985- June 1988	NEW JERSEY CITY MEDICAL CENTER RESIDENCY – INTERNAL MEDICINE 50 Baldwin Avenue Jersey City, NJ. 07304
MEDICAL SCHOOL Sept. 1981-June 1984	AMERICAN UNIVERSITY OF THE CARIBBEAN MEDICAL DOCTOR Montserrat, West Indies
COLLEGE Aug 1977- June 1981	BRADLEY UNIVERSITY BACHELOR OF SCIENCE 1501 West Bradley Avenue Peoria, IL
HIGH SCHOOL GRADUATION–JUNE 1977	CARACAS INTERNATIONAL COLLEGE Caracas, Venezuela

PROFESSIONAL EXPERIENCE

- 2005 - Present Chief of Staff
Chairman of the Medical Staff Executive Committee
Jackson North Medical Center
160 NW 170th Street
Miami, FL 33169
- January 2002 - Present Director of Lipid Clinic
Miami International Cardiology Consultants, Inc.
21097 NE 27th Court, Suite 100
Aventura, FL 33180
- January 2001 - December 2006 Former Chief of Cardiology
Aventura Hospital
20900 Biscayne Blvd
Aventura, FL 33180
- August 1997 - Present Miami International Cardiology Consultants, Inc.
Partner
21097 NE 27th Court Suite 100
Aventura, FL 33180
- February 1992 - August 1997 Howard B. Reinfeld, M.D., P.A.
1380 N.E. Miami Gardens Drive, Suite 140
North Miami Beach, FL 33179
- July 1991 - February 1992 Phillip Samet Cardiology Associates
Non-Invasive Cardiovascular Laboratory
Assistant Director
4300 Alton Road
Miami Beach, FL 33140
- July 1989 - June 1991 Mount Sinai Medical Center
Cardiovascular Fellowship
4100 Alton Road
Miami Beach, FL 33140
- July 1988 - June 1989 Humana Health Care Plan
Assistant Director
Hollywood, FL 33023

EXAMINATIONS

November 1991	Board Certified in Cardiovascular Disease
September 1988	American Board of Internal Medicine Certification # 121676

PROFESSIONAL ASSOCIATIONS

American Medical Association
Dade County Medical Association
American College of Physicians
American College of Cardiology

HONORS AND BOARD CERTIFICATIONS

November 1991	Board Certified in Cardiovascular Disease Recertified in Cardiovascular Disease (November 2002)
September 1988	Board Certified in Internal Medicine Florida Medical License #4133391994
1994	Controlled Substances Registration Certification (DEA) # BA1365560

RESEARCH EXPERIENCE:

Principal Investigator:

1. AXSYM BNP: Axis Shield BNP Clinical Study.
2. A-HeFT: African American Heart failure Trial.
A placebo control trial of BI-DIL added to standard therapy
in African American patient with patient with congestive heart failure.
3. A six-week, randomized, open label, to comparative study to evaluate the efficacy and safety of Rosuvastatin and Atorvastatin in the treatment of Hypercholesterolemia in Hispanic subjects.

RESEARCH EXPERIENCE continuation:

4. X-A-HeFT Trial: A open label extension trial of BiDil Added to Standard Therapy in African American Patients
5. ACCOMPLISH: A prospective, multinational, multicenter, double-blind randomized, active control trial to compare the effect of Lotrel (amlodipine/benazapril) to benazapril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high-risk hypertension. ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) Nov 2003 to present.
6. ATHENA: A Placebo-Controlled Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter
7. IMPROVE IT: A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial)
8. CUSP: An 8-Week Randomized, Double-Blind, Placebo Controlled Trial Examining The Efficacy And Safety of Caduet In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population
9. AGELESS: A 36 week randomized, double-blind, parallel group, multi-center, active-controlled, optional titration study comparing an aliskiren based regimen to a ramipril-based regimen in patients [greater than or equal to] 65 years old with systolic essential hypertension.
10. DORADO-AC: A Phase 3 Randomized, Double-Blind, Placebo – and Active-Controlled, Multi-Center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo
11. ALTITUDE: A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality(Will start October 2007)

RESEARCH EXPERIENCE continuation:

12. ARISTOTLE: A Warfarin controlled, randomized, double-blind, parallel arm study to evaluate efficacy and safety of Apixaban in preventing stroke and systemic embolism in subjects with nonvalvular atrial fibrillation.
13. M&M: A double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular risk in stable CHD patients, with a documented recent Acute Coronary Syndrome

Sub-Investigator:

1. EARLY-ACS: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation acute Coronary Syndrome
2. STRADIVARIUS: Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by IVUS (Intra Vascular Ultrasounds), in overweight patients with clustering risk factors